Barclays PLC Acquires 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Barclays PLC increased its holdings in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 130.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 54,810 shares of the company’s stock after buying an additional 30,990 shares during the period. Barclays PLC’s holdings in Werewolf Therapeutics were worth $116,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. PFM Health Sciences LP boosted its position in shares of Werewolf Therapeutics by 4.9% in the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after purchasing an additional 157,673 shares in the last quarter. Millennium Management LLC raised its stake in Werewolf Therapeutics by 96.4% during the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after buying an additional 544,881 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Werewolf Therapeutics by 6.3% in the third quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after acquiring an additional 40,692 shares in the last quarter. State Street Corp grew its stake in shares of Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after acquiring an additional 52,528 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Werewolf Therapeutics by 103.1% during the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after acquiring an additional 86,800 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Trading Up 5.9 %

Shares of NASDAQ:HOWL opened at $1.44 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics, Inc. has a 1 year low of $1.31 and a 1 year high of $8.19. The company has a market cap of $64.17 million, a P/E ratio of -0.94 and a beta of 0.38. The stock’s fifty day moving average price is $1.63 and its 200-day moving average price is $2.07.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HOWL. JMP Securities dropped their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.